Biohaven Ltd. (NYSE:BHVN) Shares Acquired by Alyeska Investment Group L.P.

Alyeska Investment Group L.P. raised its stake in Biohaven Ltd. (NYSE:BHVN - Free Report) by 129.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 106,351 shares of the company's stock after acquiring an additional 60,000 shares during the period. Alyeska Investment Group L.P. owned 0.11% of Biohaven worth $3,972,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. HighTower Advisors LLC raised its position in shares of Biohaven by 6.1% during the 4th quarter. HighTower Advisors LLC now owns 5,870 shares of the company's stock worth $219,000 after buying an additional 335 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Biohaven by 0.5% during the third quarter. Franklin Resources Inc. now owns 79,705 shares of the company's stock valued at $4,206,000 after buying an additional 412 shares in the last quarter. FSC Wealth Advisors LLC boosted its position in Biohaven by 3.3% during the 4th quarter. FSC Wealth Advisors LLC now owns 15,500 shares of the company's stock worth $579,000 after acquiring an additional 500 shares during the period. Prudential Financial Inc. grew its position in Biohaven by 9.4% during the fourth quarter. Prudential Financial Inc. now owns 5,980 shares of the company's stock valued at $223,000 after purchasing an additional 514 shares in the last quarter. Finally, Amalgamated Bank increased its stake in shares of Biohaven by 21.9% in the fourth quarter. Amalgamated Bank now owns 2,929 shares of the company's stock worth $109,000 after acquiring an additional 527 shares during the last quarter. Institutional investors and hedge funds own 88.78% of the company's stock.

Insider Activity at Biohaven

In related news, Director John W. Childs bought 32,700 shares of the company's stock in a transaction on Tuesday, March 4th. The shares were acquired at an average price of $30.47 per share, with a total value of $996,369.00. Following the transaction, the director now owns 2,320,571 shares of the company's stock, valued at $70,707,798.37. The trade was a 1.43 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 16.00% of the stock is owned by insiders.

Biohaven Stock Down 0.2 %

Shares of Biohaven stock traded down $0.05 on Friday, hitting $20.20. The stock had a trading volume of 1,105,302 shares, compared to its average volume of 1,179,624. The stock's 50-day simple moving average is $23.44 and its two-hundred day simple moving average is $35.48. Biohaven Ltd. has a one year low of $15.79 and a one year high of $55.70. The stock has a market cap of $2.06 billion, a price-to-earnings ratio of -2.16 and a beta of 1.18.

Biohaven (NYSE:BHVN - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.29). As a group, equities analysts predict that Biohaven Ltd. will post -8.9 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on BHVN shares. William Blair upgraded shares of Biohaven to a "strong-buy" rating in a report on Thursday, April 24th. Morgan Stanley decreased their target price on Biohaven from $69.00 to $63.00 and set an "overweight" rating on the stock in a research report on Friday, March 7th. Deutsche Bank Aktiengesellschaft set a $60.00 price target on shares of Biohaven and gave the company a "buy" rating in a report on Thursday, March 20th. Royal Bank of Canada restated an "outperform" rating and set a $61.00 target price on shares of Biohaven in a research report on Tuesday, March 4th. Finally, Robert W. Baird cut their price target on shares of Biohaven from $60.00 to $57.00 and set an "outperform" rating for the company in a report on Monday, April 28th. Fourteen equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $62.54.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.